and you, morning, Thank everyone. good Kim,
is today our me Officer. Church, Joining Financial Chief Jeffrey
cancer. and our be on Khursheed treatment development Chief Dr. provide immunotherapy remarks. ovarian programs IMNN-XXX, for prepared of interleukin Anwer, which XX the places, was In with addition, is end our which as update GEN-X, the the Scientific with available prophylactic Officer, our Q&A will during of at previously will modality our vaccine session Today, advanced an known our I
and do believe again in vision provide reminded important on for future. where I'll an investors investors it some to are update a briefly March, today the our During detail. our of I company I as in key going call various is we understand our our for Then because programs. last strategies so I'll conference
driver of to unprecedented approaches DNA-based medicines. immune will currently and of tightly protein that nonviral because say reach novel DNA by disease. We future create believe an medicines of diversity infectious the Imunon that system the developing are of technology. in harnessing focused nonviral a and recovered immuno-oncology power potential the of I on DNA key the and abundance that is beyond global has the help be
not for Our platform device DNA does a a require or virus facilitating delivery.
addition, our and and is the manufacturing not be to does can redosed, patients easily scalable In medicines administration require painful straightforward electroporation.
to or which and choices, to outsource how the advance platform whether these approach DNA designed we Our guide drug advance strategic is infrastructure, we to our deliver with opportunity scope creating long we development, DNA over medicines collaborators strategy established we build and requires full do do programs make nonviral us the patients with capabilities clear how, modality the navigate for devote several which internally investors. development which we we choices, and and patients strategic and of to term, and reaching to -- including X capital programs on alone much that value principles
asset an as development First immuno-oncology our is opportunity. on focus
care. unmet is survival and characterized of where with strategy and burden indications immunological current Our compared an a pursue the can risk progression both substantive medical to standard disease the high improve by approach of need,
immune in safety pushing study profile. IL-XX, tumor in proteins system stimulates XXX IMNN-XXX a clear how a potentially of program that is expresses CBA is adaptive immune is modality TheraPlas an example cancer. the from the of innate is IL-XX. XXX type. in system the for of XXX system. a first The natural ovarian as the cure NCX suppressing our and II one developed cells advanced know, cytokines. and currently a you of T-cells such innovation Phase is expression of Imunon response with IL-XX our This asset. immune example in activates difficult-to-treat plasmid both in expression sugar is the cytokine good boundaries
We new optimization, are immune with include second development is now developing antigen on the This modality acid modifier cancer modality to and along single selection on the based option neoantigen for a sector. nucleic of the personalized potent a vaccines.
Developing model keep the as our is and our promising partnership and strategy. on melanoma just out represents an licensing to our modality modality. is a in mice, It plan the in a logical vaccines will strategy updated you immune business prophylactic response tumor extension We also specific opportunity a antigens. started induce against second progress. we long-lasting program our and It to vaccine of prong prophylactic
for I As available pathogenic of with need discover commercially do day. fewer pathogens vaccine. viruses More actually viruses we XX having And is urgent technologies vaccine X% pathogens a described new discovered than last quarter, new every since the XXXX. than were
it's vaccines enormous. market for $XX So and for global Even before prophylactic expected is XXXX. in $XXX reach clearly, to about the billion billion, COVID, vaccines was the market
reason the may so are The modality current that technologies. the of has characteristics it we several about is vaccine place because shortcomings excited address
of is health modified efficiency [indiscernible] attributes that benefits infectious a convenience is refrigerated the to and vaccines For authorities. transmission create engineered various flexible with against emerging temperatures. And extremely of be also include and plug-and-play durability These strategy advantage, easily diseases safety example, global of manufacturing valuable are and by [indiscernible] of standard to a against multitude pathogens. stability protection,
and powerful in various have Phase seek is we will establish study and pursuing vaccines interest. to conversations, of the conversations most then pathogens human of develop platform important establish we for a productive and the to We've this pathogens. objective nondilutive urgent are had with ensure government I agencies out-license and continue partnerships to to Our and/or to safety to our technology efficacy
these more in effective are We the delighted reaction have vaccines progress our received more from with we making DNA and appealing. agencies regarding
strategic elements of of core business. principle the our on vertical Our third integration focuses the
that we Our can control so interest vendors attract while the goal quality. here and is lines on corporate minimizing costs, partners to time of dependence
Our range is of capabilities impressive.
pathogen protein or engineered. human any be can scientists proteus the from our to example, For select
laboratory have method support testing to We R&D product development. capability and
studies. conduct QC to our the of variety We a have experiments labs And models. raw also and run laboratory in and stability animal and materials, to finished GMP to testing have expertise disease products test conduct our capacity to
We and developed also DNA systems. plasmids nanoparticle have facilitating for scale capabilities manufacturing pilot in-house
The complete allow next of capability. testing integration meaning in design, our all step vertical Phase strategy aspects scale build to to pilot to GMP produce is to to control manufacturing bedside product capabilities and a bench our materials upon X Imunon
our expression neurovariants tools a array comprehensive services. addition, are and we investment Technologies, construct now to CRISPR in RNA and just gene weeks owing In in against using to transonic vaccines strategic able of
has and costs creating by chain. lines than strategy integration allowed us and vertical a more high-quality reduce to supply Our reliable, predictable time while XX%,
bedrock long-term business the strategic of Lastly, our pillar, fourth model, collaborations. which our concerns is
All with to a obtain is strategy. of execute placid and in forces and agreement formulations to our attract will that in programs for recent have end, corporate infectious to using non-dilutive time To research our partners. to internal modality. signed Wistar develop several Joining cost January, the allow first way to expand great our we collaborative Institute development our partners new our the months. us our control we with support funding of vaccine capabilities accelerate capabilities, development these lines the goal formed In diseases important both collaborations
center. XXXX. company, with research, November vaccines entered vaccine an systems and we on Therapeutics, in biomedical global our a on acid into focused builds in developing with nucleic lipid delivery which biotechnology agreement the This their and for agreement therapeutics is based immunotherapy our is Wistar upon collaboration is Acuitas and nanoparticles, leader
to We initiate formed Breakthrough in also Foundation an us with niche innovative nondilutive new clinical programs allows alliance ovarian indications that like obtain the funding cancer. Cancer to
We Phase bevacizumab, study IMNN-XXX ovarian expect otherwise advanced few known combination as with a in in first in in enrolled a the cancer. be patient XX-patient with to Avastin I/II weeks
Sidney expand expect throughout at the is the our several at Cancer conferences Sloan at Research services intelligence of The was partially the Cancer quarter. the Hopkins artificial treatment Kimmel trial, analysis, the which study. for the is participation during Institute [indiscernible] Core Cancer delighted Later, of we presented first knowledge at will Johns paradigm. genomic Memorial company's at funding Center. were important MIT, and First, Massachusetts Comprehensive of that and and Institute at Center Anderson University Technology additional Center. provide Integrative biomarker Kettering Cancer the We the cancer expected including to work the Texas
system. the of a liquid DNA single Among with broad -- virus, immunity for ability a delivery device passing generated nanoparticle to is this modality the or of from This [indiscernible] promising spectrum formulations. achieve to our Khursheed vaccine Anwer, at the presented preclinical in reviewed We Dr. preclinical advancing promising Scientific Chief the company's data Officer, data to was modality ability topics and date. mid-XXXX. technology [indiscernible] technology multivalent very plasmid independent our device work delivery our presented
comparison, in dose durable that data than a an that activity would many The is presented models, vaccines. robust the on mRNA similar and robust response take for past to characterize next-generation responses features the commercial I a protection comparable months, XX goes to and important [indiscernible] -- a detectable that such cellular booster year more vaccine humoral a in point out preclinical want advantage. protection out box desirable immunogenicity
vaccine superior a our comparison. the protective protection vaccine immunity against in demonstrated immune additional of disease. memory versus And have contributes layer quality provide dose We and lastly, creates that cells severe to that Amerinet an single
a modality X shelf distinguishing on rapid to booster than advantages at scalable in our March, In receive addition, had Based our manufacturing. and including program life compelling consultation pre-IND vaccine. class U.S. a and X degrees ability the applied with data [indiscernible] in months we guidance FDA greater proposed vaccine, on for for the for the commercial for simple, for important this
to to submit powerful and our and/or the to utilization establish human the our platform establish then and platform safety of of a our Phase I [indiscernible] an technology IND pharmaceutical in objective companies pathogens seek develop is quarter this partnerships to to vaccines this license in for year. We expect of fourth interest. Again, study of the for application efficacy to
of Jean in regimen, Cancer to step regimens prestigious X-week compliance. the the dosing human every AACR Conference. stimulation once therapy the model. is the treatment X every the Association an end ovarian Vice and regimen important improve doses Boyer best particularly demonstrated once immune It to X-week to April, that of of tumor X at Boyer, the Thus, and acceptability presented XXX response with Research, least studies while tested, patient and is regimens Imunon's superiority comparability showing exploring tumor of developing cancer Preclinical Dr. burden. for more weekly IMNN-XXX Of reported week warranted. in to President the Subsequent quarter IDA Research respect Dr. poster once in the to a in demonstrated the American regimen every first the cumbersome
cancer, to outline expect want study call value-creating Before I our compelling the X months. next upon reached we XX expect we second to more ovarian top year, Phase III/IV over XXX material to milestones I/II patients last the I financial interim turn And to we OVATION half of several report Building with full set Church enrollment of by for XXXX. Jeff of Stage results an then his X which results in the to review, our mid-XXXX. in report line interim additional over data expect
for to study data patients of III this in ago, the [indiscernible]. rates data Also care interim had X for with arm. of our XXX with compared [indiscernible] Those a [indiscernible] standard resection reminder, the this vaccine announced patients surgical who a XX for surgery. in year, CRS an file in improvement debulking vaccine cores XX chemotherapy and in half proof-of-concept expect the with showed in undergone year response combination traded control reported chemotherapy we the interval As second and IND
XXXX, of be of and for results on first combination to Moving XXX results half and we'll first study interim study [indiscernible] bevacizumab. sharing the X the for
turn over Now call Jeff. I'll the to
